Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

530 trials

NCT07194044
Recruiting
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Phase 1 · United States · 21 sites
Registry update: 25 Sept 2026
NCT07357519
Recruiting
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Phase 1/2 · United States · 2 sites
Registry update: 1 May 2026
NCT07410676
Recruiting
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/2 · China · 1 site
Registry update: 18 Feb 2026
NCT07172958
Recruiting
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Phase 1 · United States · 2 sites
Registry update: 13 Aug 2026
NCT07169344
Recruiting
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Phase 2 · Norway · 4 sites
Registry update: 28 Jan 2026
NCT07173972
Recruiting
Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Phase 2 · Norway · 2 sites
Registry update: 28 Jan 2026
NCT07144254
Recruiting
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Phase 1 · United States · 2 sites
Registry update: 19 Oct 2026
NCT07222735
Recruiting
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
Phase 1 · United States · 1 site
Registry update: 9 Feb 2026
NCT07227571
Recruiting
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Phase 1 · United States · 1 site
Registry update: 1 Sept 2026
NCT06898970
Recruiting
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
Phase 2 · United States · 1 site
Registry update: 1 Sept 2026
NCT07174427
Recruiting
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Phase 3 · Japan · 3 sites
Registry update: 28 Sept 2026
NCT07920835
Recruiting
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
Phase 2 · China · 1 site
Registry update: 6 Nov 2026
NCT06981637
Recruiting
Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Phase 2 · Taiwan · 7 sites
Registry update: 2 Jul 2026
NCT07359053
Recruiting
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Phase 2 · China · 1 site
Registry update: 22 Jan 2026
NCT07447050
Recruiting
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Phase 2 · United States · 1 site
Registry update: 3 Mar 2026
NCT07148050
Recruiting
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Phase 1 · United States · 1 site
Registry update: 17 Feb 2026
NCT07252739
Recruiting
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2 · Chile, China, Spain, Finland, Greece, Hong Kong, Italy, South Korea, Netherlands, Poland, Thailand, Ukraine, United States · 45 sites
Registry update: 2 Sept 2026
NCT07596693
Recruiting
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
Phase 1 · China · 1 site
Registry update: 19 May 2026
NCT07071727
Recruiting
Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas
Not applicable · Netherlands · 6 sites
Registry update: 19 Feb 2026
NCT07193550
Recruiting
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Phase 2 · United States · 1 site
Registry update: 25 Sept 2026

Ordered by registry start date. Freshness and sponsorship never change the order.